QuickStart*
Patients prescribed Qfitlia for the first time can receive up to 6 months of product while their insurance coverage is pending.
FOR US RESIDENTS ONLY
Every person’s situation is different, which is why we work directly with you to help identify the financial assistance programs you may be eligible for.
We can help you understand more about treatment with Qfitlia by connecting you with a dedicated Therapeutic Education Manager (TEM). TEMs will not provide personal medical advice. For all questions about your individual health needs, consult with your treating physician.
Our team works with you and your care team to verify your insurance coverage and get you started on Qfitlia as efficiently as possible.
Patients prescribed Qfitlia for the first time can receive up to 6 months of product while their insurance coverage is pending.
* Claims for free products dispensed through the QuickStart program shall not be submitted to any third-party payer, public or private (eg, private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.
If you’re having trouble paying for Qfitlia, HemAssist may be able to help if you're eligible. Get your treatment for as little as $0, with an annual maximum savings up to $20,000 with no income caps.†
† Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc, to pay in part or in full for their Qfitlia prescription. Not valid where prohibited by law. Savings by patients may vary depending on their out-of-pocket costs. The Program is intended to help patients afford their Qfitlia prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the Program may change its terms.
All programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.
Provides the guidance and education you may need throughout your Qfitlia journey, including information about the dosing adjustment process, supplemental injection training, information about antithrombin testing, and ongoing support as needed.
Your TEM will not provide personal medical advice. For all questions about your individual health needs, please speak with your doctor.
Your Case Manager is available to assist with navigating insurance coverage and identifying available financial support for eligible patients.
Sanofi Community Relations and Education (CoRe) Managers are dedicated to patient education and empowering those within the hemophilia community through one-to-one communication, as well as through community events and conferences.
Qfitlia can cause SERIOUS SIDE EFFECTS, including:
Abnormal blood clotting (thrombotic events): Serious blood clots have occurred in people treated with Qfitlia. Qfitlia can cause blood clots to form in the blood vessels in your arms, legs, lungs, heart, brain, eyes, or head. Your risk of blood clots is greater if your antithrombin (AT) blood level is persistently less than 15% or if you have certain other conditions. Your healthcare provider (HCP) will check your AT blood levels before and during treatment with Qfitlia
Gallbladder disease: Qfitlia can cause gallstones and inflammation of your gallbladder, which might require surgery to remove your gallbladder. Tell your HCP right away if you develop stomach pain, indigestion, nausea, or vomiting. Your HCP may temporarily or permanently stop Qfitlia if you develop any of these symptoms
What is the most important information I should know about Qfitlia?
Qfitlia helps your blood form clots. Do not stop using Qfitlia without talking to your HCP. If you miss doses or stop using Qfitlia, you may no longer be protected against bleeding.
Use of a clotting factor concentrate (CFC) or bypassing agent (BPA) to help protect against bleeding must be stopped within 7 days after your first dose of Qfitlia.
Your HCP may prescribe on-demand CFC or BPA if you bleed during treatment with Qfitlia. Carefully follow your HCP’s instructions regarding when to use on-demand treatment with CFC or BPA, including the prescribed dose and timing of the CFC or BPA.
Get medical help right away if you get any of these signs or symptoms of blood clots during or after treatment with Qfitlia:
What are the possible side effects of Qfitlia?
Qfitlia can cause other serious side effects, including an increase in your blood liver enzymes. Your HCP will do blood tests to check your liver function before and during treatment with Qfitlia
The most common side effects of Qfitlia include viral infection, common cold symptoms, and bacterial infection
These are not all the possible side effects of Qfitlia.
What should I tell my HCP before using Qfitlia?
Tell your HCP about all of your medical conditions, including if you have liver problems, a history of gallbladder disease, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed
Females who are able to become pregnant: Hormonal birth control may increase your risk of blood clots if used during treatment with Qfitlia. Talk to your HCP about effective forms of non-hormonal birth control you can use before starting and during treatment with Qfitlia
Tell your HCP about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements
